CBD reduced MS-like disease severity in mice by suppressing harmful immune cells and brain inflammation | Research

The takeaway

CBD treatment at disease onset ameliorated MS-like disease in mice by inhibiting pathogenic T cells and reducing spinal cord microglial activation, through mechanisms independent of CB1 and CB2 receptors.

Read this if you have MS and are interested in the science behind CBD's potential anti-inflammatory effects.

CBD effects were independent of CB1 and CB2 cannabinoid receptors

What the researchers found

Researchers used an experimental autoimmune encephalomyelitis (EAE) model in mice, the standard animal model for multiple sclerosis. CBD treatment beginning at disease onset reduced the severity of clinical signs.

CBD's benefits were accompanied by reduced axonal damage, less inflammation, decreased microglial activation, and reduced T-cell recruitment in the spinal cord.

In laboratory tests, CBD directly inhibited the proliferation of myelin-attacking T cells at both low and high concentrations of the myelin antigen. This effect was not mediated through CB1 or CB2 cannabinoid receptors, indicating CBD worked through a different, non-cannabinoid mechanism.

The non-psychoactive nature of CBD made it a potentially safer alternative to THC-based treatments for neuroinflammatory conditions.

Why it matters

The finding that CBD worked through non-cannabinoid receptor mechanisms expanded the understanding of how CBD exerts therapeutic effects and suggested it could complement existing MS treatments.

The numbers in context

CBD ameliorated EAE clinical signs. Reduced axonal damage, inflammation, microglial activation, and T-cell recruitment in spinal cord. Inhibited MOG-specific T-cell proliferation at low and high antigen concentrations. Effects independent of CB1 and CB2 receptors.

How the study worked

Preclinical study using EAE induced by myelin oligodendrocyte glycoprotein (MOG) in C57BL/6 mice. CBD administered at disease onset. Immunocytochemistry and cell proliferation assays evaluated effects on microglial activation and T-cell proliferation. CB1 and CB2 receptor independence confirmed.

What this study cannot tell us

Mouse EAE model does not perfectly replicate human MS. CBD was given at disease onset, not after established disease. The non-CB1/CB2 mechanism was not fully identified.

How to read the evidence

Well-designed preclinical study with mechanistic analysis, but limited to mouse EAE model which does not fully replicate human MS.

When this study was published

Published in 2011. CBD research for neuroinflammatory conditions has expanded.

The bigger picture

This study provided mechanistic evidence supporting CBD as a potential MS treatment, with the non-CB1/CB2 mechanism suggesting it could work alongside traditional cannabinoid-based therapies.

Questions still open

Through which receptor does CBD exert its anti-inflammatory effects in EAE? Would CBD be effective in established MS, not just at disease onset?

Common questions

Could CBD help with multiple sclerosis?

In a mouse model of MS, CBD reduced disease severity, axonal damage, and brain inflammation. It worked through a mechanism independent of typical cannabinoid receptors, suggesting a unique anti-inflammatory pathway.

How is CBD different from THC for MS?

Unlike THC, CBD does not produce psychoactive effects and appears to work through different receptor mechanisms. In this study, CBD's MS benefits were independent of CB1 and CB2 receptors, while THC primarily works through these receptors.

Read the original research

Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice.

British journal of pharmacology, 163(7), 1507-19

View on PubMed ↗Publisher’s paper ↗

Citation

Kozela, Ewa; Lev, Nirit; Kaushansky, Nathali; Eilam, Raya; Rimmerman, Neta; Levy, Rivka; Ben-Nun, Avraham; Juknat, Ana; Vogel, Zvi. (2011). Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice.. British journal of pharmacology, 163(7), 1507-19. https://doi.org/10.1111/j.1476-5381.2011.01379.x